# 253 ‒ Hormone replacement therapy and the Women’s Health Initiative: re-examining the results

**Channel:** Peter Attia MD
**Upload Date:** 2023-05-08
**URL:** https://www.youtube.com/watch?v=8bRuzA-qd0s
**Duration:** 80 minutes

## Description

Watch the full episode and view show notes here: https://bit.ly/3HJxWwn
Become a member to receive exclusive content: https://peterattiamd.com/subscribe/
Sign up to receive Peter's email newsletter: https://peterattiamd.com/newsletter/

JoAnn Manson is a world-renowned endocrinologist, epidemiologist, and Principal Investigator for the Women’s Health Initiative (WHI). In this episode, she dives deep into the WHI to explain the study design, primary outcome, confounding factors, and nuanced benefits and risks of hormone replacement therapy (HRT). JoAnn reflects on how a misinterpretation of the results, combined with sensationalized headlines regarding an elevated risk of breast cancer, led to a significant shift in the perception and utilization of HRT. From there, they take a closer look at the breast cancer data to separate fact from fiction. Additionally, JoAnn gives her take on how one should weigh the risks and benefits of HRT and concludes with a discussion on how physicians can move towards better HRT practices. 

We discuss:
Intro [0:00]
The Women’s Health Initiative: the original goal of the study, hormone formulations used, and potential confounders [4:15];
Study design of the Women’s Health Initiative, primary outcome, and more [16:00];
JoAnn’s personal hypothesis about the ability of hormone replacement therapy to reduce heart disease risk prior to the WHI [26:45];
The relationship between estrogen and breast cancer [30:45];
Why the WHI study was stopped early, and the dramatic change in the perception and use of HRT due to the alleged increase in breast cancer risk [37:30];
What Peter finds most troubling about the mainstream view of HRT and a more nuanced look at the benefits and risks of HRT [45:15];
HRT and bone health [56:00];
The importance of timing when it comes to HRT, the best use cases, and advice on finding a clinician [59:30];
A discussion on the potential impact of HRT on mortality and a thought experiment on a long-duration use of HRT [1:03:15];
Moving toward better HRT practices, and the need for more studies [1:10:00]; and
More.


--------
About:

The Peter Attia Drive is a deep-dive podcast focusing on maximizing longevity, and all that goes into that from physical to cognitive to emotional health. With over 60 million episodes downloaded, it features topics including exercise, nutritional biochemistry, cardiovascular disease, Alzheimer’s disease, cancer, mental health, and much more.

Peter Attia is the founder of Early Medical, a medical practice that applies the principles of Medicine 3.0 to patients with the goal of lengthening their lifespan and simultaneously improving their healthspan. 

Learn more: https://peterattiamd.com

Connect with Peter on:
Facebook: http://bit.ly/PeterAttiaMDFB
Twitter: http://bit.ly/PeterAttiaMDTW
Instagram: http://bit.ly/PeterAttiaMDIG

Subscribe to The Drive:
Apple Podcast: http://bit.ly/TheDriveApplePodcasts
Overcast: http://bit.ly/TheDriveOvercast
Spotify: http://bit.ly/TheDriveSpotify
Google Podcasts: http://bit.ly/TheDriveGoogle

Disclaimer: This podcast is for general informational purposes only and does not constitute the practice of medicine, nursing, or other professional healthcare services, including the giving of medical advice. No doctor-patient relationship is formed. The use of this information and the materials linked to this podcast is at the user's own risk. The content on this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Users should not disregard or delay in obtaining medical advice for any medical condition they have, and they should seek the assistance of their healthcare professionals for any such conditions. I take conflicts of interest very seriously. For all of my disclosures and the companies I invest in or advise, please visit my website where I keep an up-to-date and active list of such companies.

## AI Summary

Here's my comprehensive analysis of this episode:

**1. EXECUTIVE SUMMARY**
This episode features Dr. Joanne Manson, a principal investigator of the Women's Health Initiative (WHI), discussing the study's findings and implications regarding hormone replacement therapy (HRT). The conversation focuses on how the WHI results were misinterpreted, leading to a dramatic reduction in HRT use, even among women who could have benefited from it. The discussion emphasizes the importance of timing, formulation, and individualization in HRT decisions.

**2. KEY MEDICAL/SCIENTIFIC POINTS**
- WHI included ~27,000 women total: ~17,000 in estrogen+progestin trial, ~10,000 in estrogen-alone trial [00:22:24]
- Average age of participants was 63 years [00:13:50]
- Only 7% of participants were on statins at study start, increasing to 25% during the trial [00:17:10]
- Study found 1 additional case of breast cancer per 1,000 women per year in the E+P arm [00:40:33]
- Estrogen-alone arm showed reduction in breast cancer risk [00:41:05]

**3. HEALTH OPTIMIZATION TIPS**

Universal Recommendations:
- HRT decisions should be individualized based on age, symptoms, and health status [01:01:38]
- Women should seek clinicians with specific training in menopause management [01:01:38]

Context-specific Recommendations:
- Best candidates for HRT are women in early menopause with moderate to severe symptoms [01:04:05]
- Women can find certified menopause practitioners at menopause.org [01:15:54]

**4. SUPPLEMENTS & MEDICATIONS**

Medications discussed:
- Conjugated equine estrogen (CEE) [00:15:35]
- Medroxyprogesterone acetate (MPA) [00:15:35]
- Bioidentical estradiol [01:10:06]
- Micronized progesterone [01:10:23]

**5. BIOMARKERS & TESTING**
- Annual mammograms were required during the study [01:09:49]
- Breast density was monitored as a risk factor [01:10:06]

**6. NOTABLE QUOTES**
"Timing is everything when it comes to hormone therapy" [01:04:05]

"The pendulum has swung from hormone therapy being good for all women in the 1980s and 1990s, to being bad for all women in the early 2000s, to now coming to rest in a more appropriate place - that hormone therapy is good for some but not all women." [01:04:05]

**7. FOLLOW-UP QUESTIONS**
1. What are the specific differences in outcomes between transdermal and oral estrogen delivery?
2. How do modern bioidentical hormones compare to CEE in terms of cardiovascular effects?
3. What is the optimal duration of HRT use for maximum benefit/risk ratio?

Would you like me to expand on any of these sections or provide additional details from other categories?
